Δευτέρα 22 Αυγούστου 2016

SLC44A4, an ADC target for pancreatic and prostate cancer

Here we report the development of an antibody-drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters which we show to be markedly upregulated in a variety of epithelial tumors, most notably prostate and pancreatic cancer. SLC44A4 is normally expressed on the apical surface of secretory epithelial cells but in cancer we show expression is not restricted to the luminal surface in advanced and undifferentiated tumors. ASG-5ME consists of a human IgG2 anti-SLC44A4 antibody conjugated through a cleavable linker to the microtubule-disrupting agent, monomethylauristatin E. It has potent anti-tumor activity in both cell line and patient-derived xenograft models of pancreatic and prostate cancers. Combination studies with ASG-5ME and nab-paclitaxel demonstrated combination effect in both pancreatic and prostate tumor models. Altogether, the data presented here suggests that ASG-5ME may have the potential to offer a new therapeutic option for the treatment of pancreatic and prostate cancer.



from Cancer via ola Kala on Inoreader http://ift.tt/2bb2z1O
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου